FFRangio System vs CVI42
AI Verdict
Choose FFRangio System if…
Choose the FFRangio System if your primary need is real-time, non-invasive physiological assessment during coronary interventions. This tool is ideal for interventional cardiologists seeking to optimize and confirm PCI decisions by obtaining accurate, wire-free FFR guidance and advanced insights directly from angiograms, eliminating the need for pressure wires or vasoactive drugs. It excels in providing immediate feedback on lesion significance and treatment effectiveness within the cath lab setting.
View FFRangio System →Choose CVI42 if…
Choose CVI42 if your focus is on comprehensive, AI-enabled analysis of cardiac and vascular CT and MRI images for diagnostic purposes and pre-procedural planning. This platform is best suited for radiologists and cardiologists requiring advanced tools for detailed coronary plaque analysis, automated segmentation of cardiac structures, and sophisticated CMR automation for a wide range of cardiac conditions. It provides a powerful solution for in-depth image interpretation and disease characterization across various imaging modalities.
View CVI42 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | FFRangio System | CVI42 |
|---|---|---|
| Pricing | Contact vendor for pricing information. | Starts at $5,000 per license. |
| Deployment | SaaS, on-prem, hybrid | On-premise (standalone workstation or client/server) |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
FFRangio SystemTool A, FFRangio System, explicitly highlights an 'Intuitive user interface' and 'Seamless integration with cath lab boom and PACS' to simplify the operator experience during interventional procedures. While Tool B, CVI42, offers a comprehensive platform with AI automation, Tool A's focus on an intuitive, integrated workflow for a specific, high-stakes procedure suggests a higher emphasis on immediate usability in its operational context.
Clinical Value
FFRangio SystemTool A, FFRangio System, offers significant clinical value by providing wire-free and drug-free 3D FFR guidance, eliminating the need for invasive pressure wires and associated drugs, thereby reducing procedural risks and enhancing patient experience. This directly impacts interventional cardiology by optimizing and confirming PCI decisions with accurate multi-vessel FFR results. Tool B, CVI42, provides comprehensive diagnostic and planning tools across various imaging modalities, which is valuable for broader patient management, but Tool A's direct impact on reducing invasiveness in a critical procedure offers a more distinct and immediate patient benefit.
Pricing & Value
CVI42Both tools require contacting for pricing, but Tool B, CVI42, explicitly states a 'Flexible subscription that scales across CT and MR service lines' and that 'specific modules like Strain require additional licenses'. This indicates a more transparent and potentially adaptable pricing model that can be tailored to an institution's specific needs and scale, offering better perceived value. Tool A provides no details on its pricing structure beyond 'contact for pricing'.
Enterprise Readiness
FFRangio SystemBoth tools are deployed on-premise and have FDA clearance. However, Tool A, FFRangio System, explicitly states it is ISO 27001 certified for information security, which is a strong indicator of robust data protection and enterprise-level security practices. Tool B, CVI42, does not disclose similar certifications, making Tool A appear more prepared for enterprise deployment from a security and compliance standpoint.
Innovation
FFRangio SystemTool A, FFRangio System, represents a significant innovation by providing wire-free and drug-free 3D FFR guidance, transforming a previously invasive diagnostic procedure into a non-invasive one. This fundamentally changes the approach to coronary physiological assessment in the cath lab. While Tool B, CVI42, offers advanced AI-driven image analysis across multiple modalities, Tool A's innovation is more disruptive to an established clinical workflow.
Support & Docs
CVI42Tool B, CVI42, offers readily available and detailed support information, including dedicated technical support, comprehensive online documentation for various versions, archived tutorials, and a customer portal. Circle Cardiovascular Imaging also emphasizes 'world class support and clinical team' and 'Real People, Real Time Support' in multiple languages and time zones. In contrast, Tool A, FFRangio System, only provides a form to request Instructions For Use (IFU) and does not publicly detail its support structure or documentation availability.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | FFRangio System | CVI42 |
|---|---|---|
| Name | FFRangio System | CVI42 |
| Company | CathWorks | CIRCLE CARDIOVASCULAR IMAGING |
| Primary Use Case | Delivers wire-free and drug-free 3D FFR guidance for optimizing PCI decisions for patients with coronary artery disease. | AI-enabled software platform for comprehensive cardiac and vascular imaging analysis, enhancing diagnosis, planning, and patient care with advanced CT and MRI tools. |
| Core Technology/Methodology | Wire-free and drug-free 3D FFR guidance, Artificial intelligence aids in quick angiogram analysis | AI-enabled software for comprehensive cardiac and vascular imaging analysis (CT and MRI) |
| Key Feature Example 1 | Real-time FFRangio values at every point on the coronary tree | AI-automated coronary lumen and wall segmentation |
| Key Feature Example 2 | Eliminates the need for invasive pressure wires, drugs, or a guide catheter | Comprehensive coronary plaque analysis (calcified, non-calcified, low-attenuation) |
Videos
Demos, reviews, and walkthroughs featuring FFRangio System and CVI42.